IBA Business Update – Third Quarter 2023 - Seite 2

Proton Therapy

• Contract for two ProteusONE¹ proton therapy solutions finalized with Medtechnica Ltd, Tel Aviv, with first payments received
• Post period, a total system restoration and multi-year service contract was signed with Massachusetts General Hospital (MGH), IBA’s first-ever proton therapy installation, worth between USD 80-100 million, with first payment received
• 31 ongoing proton therapy projects including eight ProteusPLUS¹ and 23 Proteus ONE
• All-time record construction and installation of a ProteusONE at the UAMS Winthrop P. Rockefeller Cancer Institute, Arkansas, completed only 20 months after contract signature, and the first patient treated  
• Installation of a ProteusONE completed at the European Institute of Oncology, Milan, IBA’s second proton therapy center in Italy
• First patient treated on a ProteusPLUS system at Tata Memorial Center, Mumbai, IBA’s second proton therapy center in India
• Two proton therapy shipments made to customer sites ahead of installations starting in early 2024
• 40 service contracts now generating revenues globally

Other Accelerators (RadioPharma, Industrial)

• Five new machines sold during the period, bringing the total for the first nine months of 2023 to 13 (compared to 29 machines for the same period last year), with sales in the US, Asia (including China), and Europe
• 17 Other Accelerators installations are ongoing, six of which started in the period
• IBA continued to support the development of theranostics, with the first astatine-211 produced in Julich, Germany, using a Cyclone 30XP
• In September, IBA co-hosted the International Food Ionization Processing Symposium (IFIS), in Texas, USA, aimed at sharing information to accelerate the adoption of food ionization
• Post-period end, IBA organized a symposium in Suzhou, China, providing a 360-degree view of X-ray sterilization technology
• PanTera, the joint-venture between IBA and SCK-CEN is progressing well, both on the near-term production of actinium-225 in Belgium from mid-2024, as well as the longer-term large-scale production

Dosimetry

• Record order intake for the first nine months of 2023 with backlog standing at EUR 33.4 million
• IBA released myQA iON version 2.1 for conventional radiation therapy and proton therapy, which incorporates ScandiDos’ Delta4 Phantom+, enabling 3D measurements
• Excellent integration of new QUASAR line brand, formerly MODUS QA, with release of QUASAR Motion MR Platform, the world’s first large-scale, MR-safe motion platform

Outlook